Special Issue "Hedgehog Signaling Pathway in Cancer: Smoothened and GLI Take Center Stage"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 June 2015)
Prof. Dr. Hui-Wen Lo
The sonic hedgehog (Shh) pathway plays an important role in mediating normal development, oncogenesis, tumor progression, stem cell biology, and tumor-stroma interactions. Consequently, the Shh pathway is an attractive target for anti-cancer therapy. Although drugs targeting this pathway have produced promising clinical results for basal cell carcinoma (BCC), and despite the fact that some of these drugs are being approved by the FDA for treating BCC patients, hedgehog pathway-targeted therapy has demonstrated limited clinical efficacy against most cancer types. This disappointing outcome highlights the notion that the Shh pathway is highly complex and interactive with other signaling molecules in cells. Consequently, a deeper understanding of the pathway will help lay the foundation for improving the efficacy of Shh inhibitors and for developing novel strategies to circumvent this important pathway. Among the many players within the Shh pathway, the smoothened (SMO) and glioma-associated oncogene homologs (GLI) serve as key positive regulators. Somatic mutations can be detected in SMO and several components of the pathway, including in patched-1 (PTCH) and SUFU (suppressor of fused). In addition to genomic abnormalities, post-translational modifications regulate GLI1 and many components of this important pathway. GLI1 can be regulated by hedgehog ligand-independent, non-canonical pathways. Recently, GLI1 has been recently shown to undergo alternative splicing to yield truncated GLI1 (tGLI1), which behaves as a gain-of-function GLI1, thus promoting tumor invasiveness and angiogenesis. In light of these recent advances, this Special Issue will focus on describing the current landscape of the Shh signaling pathway in a variety of human cancers and on providing an overview of Shh-targeted therapy (with respect to its clinical efficacy and challenges).
Dr. Hui-Wen Lo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hedgehog signaling
- stem cells
- targeted therapy
- tumor drug resistance
- tumor-stroma interactions